TABLE 5.
In vitro activity of rezafungin compared to anidulafungin and micafungin against 569 Nordic C. albicans isolates as determined by EUCAST E.Def 7.3.1
| Drug | No. with MIC (mg/liter)a: |
MIC range (mg/liter) | Modal MIC (mg/liter) | MIC50 (mg/liter) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.004 | 0.008 | 0.016 | 0.03 | 0.06 | 0.125 | 0.25 | 0.5 | 1 | 2 | ||||
| Rezafungin | 28 | 221 | 282 | 27 | 8 (8) | 2 (2) | 1 (1) | 0.016–1 | 0.06 | 0.06 | |||
| Anidulafungin | 391 | 159 | 12 (4) | 1 (1) | 5 (5) | 1 (1) | 0.004–0.25 | 0.004 | 0.004 | ||||
| Micafungin | 18 | 221 | 295 | 24 | 6 (6) | 4 (4) | 1 (1) | 0.004–2 | 0.016 | 0.016 | |||
a
Modal MICs are in boldface. The numbers of isolates with mutations in fks target genes are in parentheses. The wild-type ranges defined by WT-UL for rezafungin and by EUCAST ECOFFs for anidulafungin and micafungin are shaded.